MRC Technology Sells Its Melanocortin Receptors Programme To Pfizer Inc. (PFE)

London, June 18, 2014: MRC Technology, a technology transfer organisation, announced today that it has sold to Pfizer Inc. its melanocortin receptors (MCRs) programme, which includes a set of small molecules. Targets for these small molecules came to the attention of MRC Technology from Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London …

Catalyst Pharmaceutical Partners Set to Join Russell Microcap(R) Index

CORAL GABLES, Fla., June 18, 2014.  Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, announced today that the Company is set to join the Russell Microcap(R) Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes …